Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Unknown 1Terminated 1Completed 1

Sponsor Class

OTHER 3INDUSTRY 3NIH 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 61Gastrointestinal 14Gynecologic 12Breast 12Genitourinary 11Head & Neck 10Dermatologic 7Sarcoma 5Other solid neoplasm 3Endocrine 2CNS 1

Conditions

Advanced Solid Tumors 432Advanced Solid Tumor 352Solid Tumor 305Solid Tumors 246Mesothelioma 115Solid Tumor, Adult 76Mesothelioma, Malignant 72Carcinoma, Non-Small-Cell Lung 66Ovarian Neoplasms 47Melanoma 42Carcinoma, Renal Cell 37Colorectal Neoplasms 34Advanced or Metastatic Solid Tumors 32Uterine Cervical Neoplasms 31Stomach Neoplasms 31Solid Tumours 31Esophageal Neoplasms 30Neoplasms 27Pancreatic Neoplasms 26Squamous Cell Carcinoma of Head and Neck 25Breast Neoplasms 25Advanced Malignant Solid Tumors 25Triple Negative Breast Neoplasms 24Lung Neoplasms 24Small Cell Lung Carcinoma 23Advanced Solid Tumours 23Sarcoma 21Neoplasm Metastasis 21Advanced Malignant Solid Tumor 21Locally Advanced or Metastatic Solid Tumors 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Adenocarcinoma of Lung × Other solid neoplasm × Clear all
NCT06299163 2025-07-23

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors

Numab Therapeutics AG

Phase 1 Terminated
11 enrolled
BreastDermatologicGenitourinaryGynecologicOther solid neoplasmSarcomaThoracic

Adenocarcinoma of Lung, Mesothelioma, Malignant, Carcinoma, Renal Cell, Fallopian Tube Neoplasms, Leiomyosarcoma, Liposarcoma, Melanoma, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05498597 2023-10-19

AMT-151 in Patients With Selected Advanced Solid Tumours

Multitude Therapeutics Inc.

Phase 1 Unknown
30 enrolled
BreastGynecologicOther solid neoplasmThoracic

Adenocarcinoma of Lung, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Carcinoma, Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02485119 2018-06-04

Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies

Bayer

Phase 1 Completed
12 enrolled
BreastOther solid neoplasmThoracic

Adenocarcinoma of Lung, Mesothelioma, Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡